ArticleNorthern clinics of Istanbul2026
Biochemical and clinical outcomes of once-daily teriparatide in refractory chronic hypoparathyroidism: A single-center experience.
Article in Northern clinics of Istanbul, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic hypoparathyroidism causes disrupted calcium-phosphate balance due to parathyroid hormone (PTH) deficiency. In refractory disease, recombinant PTH (1-34) (teriparatide) can support conventional therapy. This study assessed short-term biochemical and clinical outcomes under real-word of once-daily teriparatide in refractory hypoparathyroidism.
methodsTen patients with chronic hypoparathyroidism who received subcutaneous teriparatide (20 µg/day) between January 2021 and September 2025 were retrospectively analyzed. The median duration of teriparatide therapy was 9 months (interquartile range: 4-22), with a maximum of 27 months. Clinical records, biochemical parameters, and calcium/vitamin D supplementation requirements were systematically reviewed.
resultsAlbumin-corrected calcium increased significantly at 3 months (median 7.79 vs. 6.5 mg/dL, p=0.038) but not at 6 months (p>0.05). Phosphorus decreased at 3 months (p=0.012) with a non-significant trend thereafter (p=0.06). No correlation was observed between calcium change and treatment duration (ρ=-0.8, p=0.2). All patients reported symptomatic relief and reduced intravenous calcium requirements, though complete independence was not achieved.
conclusionOnce-daily teriparatide provided transient biochemical improvement and clinical relief in refractory hypoparathyroidism but was insufficient to maintain sustained normocalcemia, suggesting possible pharmacological limitations of once-daily intermittent PTH replacement that warrant further investigation in larger prospective studies. Individualized treatment duration, alternative dosing regimens, and longer-term controlled studies are warranted to optimize therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.